Closing the data loop in AI-driven drug discovery

Pharmaceutical companies are increasingly adopting AI to combat Eroom’s Law, the trend where the cost of drug development consistently rises despite technological progress. By automating data cycles and experimental loops, these tools aim to reduce the time and capital required to bring new medications to market. This shift seeks to mitigate the financial risks of pharmaceutical research and maintain competitiveness in an industry where first-mover advantage is critical for long-term success.